As of close of business last night, Diversified Healthcare Trust’s stock clocked out at $2.43, down -6.18% from its previous closing price of $2.59. In other words, the price has decreased by -$0.1600 from its previous closing price. On the day, 729379 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of DHC’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.21.
Wells Fargo Downgraded its Overweight to Equal Weight on January 17, 2020, while the target price for the stock was maintained at $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 14 ’23 when PORTNOY ADAM D. bought 2,000,000 shares for $3.07 per share. The transaction valued at 6,132,600 led to the insider holds 23,250,019 shares of the business.
PORTNOY ADAM D. bought 1,992,259 shares of DHC for $6,026,783 on Jun 13 ’23. The Director now owns 21,250,019 shares after completing the transaction at $3.03 per share. On Jun 12 ’23, another insider, PORTNOY ADAM D., who serves as the Director of the company, bought 2,011,256 shares for $2.87 each. As a result, the insider paid 5,778,540 and bolstered with 19,257,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DHC now has a Market Capitalization of 622.68M and an Enterprise Value of 3.19B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.23 while its Price-to-Book (P/B) ratio in mrq is 0.25. Its current Enterprise Value per Revenue stands at 2.26 whereas that against EBITDA is 15.72.
Stock Price History:
Over the past 52 weeks, DHC has reached a high of $3.96, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 2.8414, while the 200-Day Moving Average is calculated to be 2.5652.
Shares Statistics:
It appears that DHC traded 1.35M shares on average per day over the past three months and 1.97M shares per day over the past ten days. A total of 240.42M shares are outstanding, with a floating share count of 215.61M. Insiders hold about 10.32% of the company’s shares, while institutions hold 76.08% stake in the company. Shares short for DHC as of Feb 29, 2024 were 6.18M with a Short Ratio of 4.59, compared to 4.57M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.57% and a Short% of Float of 2.90%.
Dividends & Splits
With its trailing 12-month dividend rate of 0.04, DHC has a forward annual dividend rate of 0.04. Against a Trailing Annual Dividend Yield of 1.54%, it implies a Forward Annual Dividend Yield of 1.65%. The stock’s 5-year Average Dividend Yield is 5.35.
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.28, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.27 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$1.05 and -$1.05 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.76, with 1 analysts recommending between -$0.76 and -$0.76.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $370.65M. It ranges from a high estimate of $372.9M to a low estimate of $367.62M. As of the current estimate, Diversified Healthcare Trust’s year-ago sales were $337.61M, an estimated increase of 9.80% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for DHC’s current fiscal year. The highest revenue estimate was $1.53B, while the lowest revenue estimate was $1.5B, resulting in an average revenue estimate of $1.51B. In the same quarter a year ago, actual revenue was $1.41B, up 7.40% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $1.61B in the next fiscal year. The high estimate is $1.64B and the low estimate is $1.58B. The average revenue growth estimate for next year is up 6.30% from the average revenue estimate for this year.
